Beatriz Mateos, EASL ILC 2021: Tenofovir in Hepatitis B Patients with COVID-19
Access all of the content
It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B.
Her presentation entitled ‘Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients’ was given at EASL ILC 2021, 23-26 June.
Questions
- What was the rationale for investigating antiviral treatments, such as tenofovir and entecavir, in the treatment of COVID-19 infection for those with chronic hepatitis B? (0:23)
- Could you briefly summarise the aims of your study, the methods used and the analysis performed? (1:00)
- What were the key clinical findings from the research? (2:23)
- Based on these findings, could tenofovir be providing a protective effect from severe COVID-19 symptoms and what could the clinical impact of these findings be? (3:09)
Disclosures: Dr Beatriz Mateos has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.